Add like
Add dislike
Add to saved papers

African American race is associated with worse sleep quality in heavy smokers.

STUDY OBJECTIVES: To examine the association of self-identified race with sleep quality in heavy smokers.

METHODS: We studied baseline data from 1965 Non-Hispanic White (NHW) and 462 African American (AA) participants from SPIROMICS with ≥20 pack-years smoking history. We first examined the PSQI's internal consistency and item-total correlation in a population with COPD. We then used staged multivariable regression to investigate the association of race and sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI). The first model included demographics; the second added measures of health status; the third, indicators of socio-economic status. We next explored the correlation between sleep quality with six-minute walk distance and St George's Respiratory Questionnaire score as COPD-relevant outcomes. We tested for interactions between self-identified race and the most important determinants of sleep quality in our conceptual model.

RESULTS: We found that the PSQI had good internal consistency, and item-total correlation in our study population of heavy smokers with-and-without COPD. AA race was associated with increased PSQI in univariable analysis and after adjustment for demographics, health status, and socio-environmental exposures (P=.02, 0.44 95%CI: 0.06 to 0.83). Increased PSQI was associated with lower post-bronchodilator FEV1 and lower household income, higher depressive symptoms, and female gender. We identified an interaction wherein depressive symptoms had a greater impact on PSQI score for Non-Hispanic White than African American participants (P-for-interaction=.01).

CONCLUSIONS: In heavy smokers, self-reported AA race is independently associated with worse sleep quality.

CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Study of COPD Subgroups and Biomarkers (SPIROMICS); Identifier: NCT01969344; URL: https://clinicaltrials.gov/ct2/show/NCT01969344.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app